Vendor Intelligence Report: PeptiAtlas

Published 13 Jun 2026. 25-page investigative report on who is behind PeptiAtlas: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 5 Finnrick lab tests, PeptiAtlas is 5 pass / 0 fail — an overall pass rate of 100%. That is a real positive signal, but it is narrow: every Finnrick result in the file is Tirzepatide, with no PeptiAtlas data for the broader GLP-1 and peptide catalog. For a Tirzepatide-only buyer, chemistry is not the main weakness in this report; for Semaglutide, Retatrutide, Cagrilintide, BPC-157, or MOTS-c, buyers are leaning on marketing rather than Finnrick product evidence.

The vendor file changes sharply once identity and facilities are tested. PeptiAtlas markets 12 years of peptide focus and major manufacturing capacity, while domain registration, certificate-transparency, and Wayback evidence place the public brand in mid-2025. Its About page also uses facility images source-matched to AmbioPharm and Bachem, meaning the strongest visual proof of production capacity belongs to other manufacturers.

Operator attribution is also not as presented. A product-page template error, sister-site contact paths, and overlapping catalogs point PeptiAtlas into a Zhengzhou Longjia / Shanghai Rise & Shine storefront family, despite a Shanghai address and multiple UK WhatsApp personas on the public site. The practical issue is accountability: the site names no legal entity, its privacy and terms pages returned 404 in the field run, and no lot-level COA verification workflow was documented.

Payment and reputation signals raise the stakes. The observed payment FAQ emphasizes crypto, peer-to-peer apps, wire, Western Union/MoneyGram, and PayPal without documented merchant-protection terms; a public Reddit post alleges a $200 BTC payment followed by blocking. Finnrick found no X or web-coupon affiliate network pushing PeptiAtlas in searched channels, so this is less a hype-vendor file than a narrow Tirzepatide chemistry positive wrapped in unresolved identity, recourse, and representation risk.

Inside the full report:

  • Complete Finnrick Tirzepatide record, methodology-divergence charts, and Appendix A lab-data table
  • RDAP, certificate-transparency, and Wayback timeline for the mid-2025 PeptiAtlas launch
  • Side-by-side facility-image comparisons tying PeptiAtlas visuals to AmbioPharm North Augusta and Bachem Bubendorf sources
  • Operator-attribution chain from template bleed-through to shrsnpeptide.com, zzljtech.com, and Zhengzhou Longjia
  • Payment-channel and buyer-recourse analysis, including the Reddit BTC non-delivery allegation caveat
  • Contact-infrastructure review covering UK WhatsApp personas, Telegram handles, missing legal pages, and exposed WordPress admin artifacts

Risk assessment

  • Misleading operating-history claims — high: peptiatlas.com registered 2025-06-21; 12-year and 362-employee claims are unsupported by supplied records.
  • Misrepresented manufacturing capability — high: AmbioPharm North Augusta and Bachem Bubendorf facility photos are used on PeptiAtlas pages as manufacturing evidence.
  • Low-recourse payment and non-delivery risk — high: Site lists crypto, wire, Western Union/MoneyGram, Zelle/Cash App/Venmo and no card checkout; a Reddit user alleges $200 BTC payment followed by blocking.
  • Missing legal entity and buyer terms — high: PeptiAtlas site names no legal entity or registration number; Privacy Policy and Terms of Service URLs returned 404.
  • Deceptive location/contact presentation — medium: Site claims Shanghai while records tie the operation to Zhengzhou Longjia; support uses multiple UK +44 WhatsApp personas.
  • Brand-confusion / multi-storefront risk — medium: Evidence links PeptiAtlas to shrsnpeptide.com, zzljtech.com, shunltirch.com, and longjiaxintide.com without an authorized-channel list.
  • Untested-product quality uncertainty — medium: Finnrick data covers only Tirzepatide; no Finnrick tests are supplied for Semaglutide, Retatrutide, Cagrilintide, BPC-157, or MOTS-c.